Platform technology
Sagitta® is RS Research’s proprietary family of drug-delivery platforms for targeted therapies, designed to deliver cytotoxic and antiangiogenic payloads and radionuclides selectively to tumor tissue and improve the therapeutic index, addressing the efficacy-toxicity trade-off.
Sagitta’s lead investigational candidate, RS-0139, has successfully completed its Phase 1 clinical trial in patients with solid tumors, providing early clinical validation for the broader translational potential of the platform family.
The lead candidate: RS-0139
The lead candidate: RS-0337
The lead candidate: RS-0139
Upon contact with water, Sagitta® Bir backbone wraps around the payload, ensuring formation of a water-soluble nanocarrier.
The lead candidate: RS-0337
Upon contact with water, Sagitta® Dui forms a micellar nanoparticle, encapsulating the second payload.
Sagitta® Radix’s design allows for precise targeting of disease sites via monoclonal antibodies (mAbs) or peptides for theranostic applications.
Why use Sagitta drug-delivery platforms to develop nanomedicines designed to improve pharmacokinetics, tumor targeting or therapeutic index?
Supporting payloads, where delivery, PK or tolerability limit clinical potential,
through conjugation to patented platforms for:
- Smart medicine with active tumor targeting
- Improved pharmacokinetics
- Clinically validated platform ready today
- Increased efficacy through better tumor accumulation, reduced side effects
- Higher and longer exposure to medicine
- Resetting patent expiry dates via making prodrugs
- Can partner to unlock the AI-driven drug development trend
Efficacy & Specificity
· Versatile structure ·
· Synergistic therapeutic effect ·
· Higher accumulation ·
Translatability
· Pharmacokinetic parameters ·
· Predictable translation to human ·
· Clinical Validation ·
Tolerability
· Reduced side effect profile ·
· Enhanced Permeability & Retention effect ·
· Biologic stimuli driven release ·
Manufacturability
· Proven GMP production record ·
· High purity ·
· Scalable for clinical GMP batches ·
Platform Technology Facts
What is Sagitta®?
Sagitta® is RS Research’s proprietary family of drug-delivery platforms for targeted therapies, designed to deliver cytotoxic and antiangiogenic payloads and radioligands selectively to tumor tissue with the aim of improving the therapeutic index.
What problem is Sagitta® designed to address?
Sagitta® is designed to address the efficacy-toxicity trade-off in oncology by improving payload delivery to tumor tissue while reducing unnecessary systemic exposure.
What is Sagitta® Bir?
Sagitta® Bir is a water-soluble polymer backbone designed to develop targeted polymer-drug conjugates. RS-0139, the lead investigational candidate, was developed with Sagitta® Bir.
What is Sagitta® Dui?
Sagitta® Dui is designed to develop dual-drug, self-assembling targeted nanoparticles. RS-0337 is the lead candidate associated with Sagitta® Dui.
What is Sagitta® Radix?
Sagitta® Radix is designed to develop targeted radiodiagnostic and radiotherapeutic (theranostic) agents using monoclonal antibodies (mAbs) or peptides.
What is Sagitta® Trois?
Sagitta® Trois is an antibody-conjugation platform with a polymer-antibody ratio (PAR) of 1-5 and multiple payloads attached per polymer, enabling drug-antibody ratio (DAR) values ranging from 9 to 35.
Which payload types can Sagitta® support?
Sagitta® is compatible with cytotoxic/antiangiogenic payloads and radionuclides. RS Research’s pipeline includes candidates of targeted chemotherapy and theranostics.
What clinical evidence supports Sagitta®?
RS-0139, a Sagitta® Bir candidate, has completed a multicenter, open-label, two-step Phase 1a/1b trial in patients with recurrent, locally advanced or metastatic solid tumors. Public topline findings include markedly improved hematologic safety compared with conventional chemotherapy, an encouraging safety and tolerability profile and promising early signals of antitumor activity.
What public Phase 1 data have been presented for RS-0139?
At ASCO 2025, RS Research presented Phase 1a dose-escalation results for RS-0139 in advanced solid tumors. The public abstract reported eight patients across three dose levels, no grade 3 or higher toxicities at 60 mg/m², and pharmacokinetic findings including an approximately 4-fold longer half-life compared with docetaxel.
How is Sagitta® connected to RS Research’s pipeline?
RS Research’s pipeline candidates are designed using Sagitta® drug-delivery platforms. The public pipeline includes candidates of targeted chemotherapy and theranostics for solid tumors.
Can Sagitta® support only chemotherapy candidates?
No. The Sagitta® platform family can address targeting needs in multiple indications, including non-oncology disease areas.
Can Sagitta® support co-development or partnering?
Sagitta® is positioned as a platform for targeted delivery across payloads and targeting approaches, creating potential for co-development, licensing and pipeline-enrichment collaborations.
Are Sagitta®-enabled candidates approved medicines?
No. RS Research develops investigational programs. This website content is for general informational purposes only, does not provide medical advice and relates to products that are not approved for general use.
Where can public clinical information about Sagitta® be found?
Public information about RS-0139, the lead asset of Sagitta® platform family, is available at the ClinicalTrials.gov record NCT04261413, the ASCO 2025 Phase 1a abstract, RS Research’s May 2026 announcement of Phase 1 completion and our latest announcements. For further information, we will be happy to connect: info@rsresearch.net
Sagitta® at a glance
| Selective tumor delivery | RS-0139 Phase 1a public data reported pharmacokinetic findings including an approximately 4-fold longer half-life compared with docetaxel. |
|---|---|
| Improved therapeutic index | Publicly disclosed Phase 1 findings for RS-0139 include markedly improved hematologic safety compared with conventional chemotherapy, an encouraging overall safety and tolerability profile and promising early signals of antitumor activity. |
| CMC | RS Research operates GMP-certified capabilities supporting its clinical development activities and international growth plans. |
Platform Family
| Platform | Description | Lead candidate or application |
|---|---|---|
| Sagitta Bir | A water-soluble polymer backbone designed to develop targeted polymer-drug conjugates | RS-0139 (Lead investigational candidate, which has successfully completed phase 1 clinical trial) |
| Sagitta Dui | A dual-drug, self-assembling targeted nanoparticle | RS-0337 |
| Sagitta Radix | A platform designed to develop targeted theranostics using monoclonal antibodies or peptides | RS-0826 |
| Sagitta Trois | An antibody-conjugation platform with high DAR | Antibody-polymer conjugates |
